XML 60 R49.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Segment Reporting [Abstract]        
Number of operating segments | segment     1  
Expenses        
Total research and development expenses $ 102,696 $ 91,399 $ 218,923 $ 198,415
Total general and administrative expenses 32,267 25,194 61,620 50,430
Total operating expenses 134,963 116,593 280,543 248,845
Segment gain from divestiture of small molecule programs 0 0 0 14,537
Loss from operations (134,963) (116,593) (280,543) (234,308)
Segment interest and other income, net 10,844 17,567 23,454 33,480
Therapeutics Segment        
Expenses        
Other research and development expenses 22,060 14,504 42,706 30,386
Personnel related research and development expenses 40,255 34,052 80,524 76,381
Total research and development expenses 102,696 91,399 218,923 198,415
Personnel related general and administrative expenses 20,115 17,105 38,853 36,190
Other general and administrative expenses 12,152 8,089 22,767 14,240
Total general and administrative expenses 32,267 25,194 61,620 50,430
Total operating expenses 134,963 116,593 280,543 248,845
Segment gain from divestiture of small molecule programs 0 0 0 14,537
Loss from operations (134,963) (116,593) (280,543) (234,308)
Segment interest and other income, net 10,844 17,567 23,454 33,480
Loss before income taxes (124,119) (99,026) (257,089) (200,828)
Therapeutics Segment | TV Programs, Including Cost Sharing        
Expenses        
External research and development expense 37,594 30,247 84,052 65,931
Therapeutics Segment | Small Molecule Programs, Including Cost Sharing        
Expenses        
External research and development expense $ 2,787 $ 12,596 $ 11,641 $ 25,717